默克公司的 Keytruda 化疗疗法在高危子宫内膜癌无病生存期 3 期试验中失败。 Merck's Keytruda therapy with chemotherapy failed Phase 3 trial for high-risk endometrial cancer disease-free survival.

默克公司的 Keytruda 疗法联合化疗在 3 期试验中未能达到高危子宫内膜癌患者手术后无病生存的主要目标。 Merck's Keytruda therapy in combination with chemotherapy failed to meet the main goal of disease-free survival in high-risk endometrial cancer patients after surgery in a Phase 3 trial. 由于试验失败，该研究的另一个主要目标——总体生存率并未得到正式测试。 The study's other main goal of overall survival was not formally tested due to the trial's failure. 子宫内膜癌始于子宫内膜，是影响子宫的最常见形式。 Endometrial cancer begins in the uterus's inner lining and is the most common form affecting the organ.